A-A-G – a triple procedure in the treatment of subretinal hemorrhages located in the posterior pole, concomitant to the exudative age-related macular degeneration. A case series report
Article Sidebar
Main Article Content
Abstract
Presentation of the author’s own results in the treatment of case series of massive subretinal hemorrhages associated with the exudative form of age-related macular degeneration, using a triple procedure of A-A-G-injections of (A) nticoagulants and (A)nti-VEGF, injected into the vitreous cavity, followed by endotamponade with expansile (G)as. The procedure was implemented in 6 patients (6 eyes) between day 2 and day 14 from the moment of sudden loss of vision and appearance of the hemorrhage. In one case, the therapy was implemented 2 months after the sudden loss of vision, because of the presence of a “fresh“ subretinal hemorrhage. Prone position was recommended for the next 5 days after treatment initiation. The average observation time was 12 months. Effects of visual improvement and hemorrhage absorption were observed in 6 patients (6 eyes). In one eye, a recurrent hemorrhage associated with RPE rupture occurred during the observation time. Retinal detachment that required surgical intervention was observed in one eye 4 weeks after the introduction of the triple procedure.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Driscoll S, Garg SJ. Managing Submacular Hemorrhage. Rev Ophthalmol. 2014; Jan: 40-5.
3. Abboud M, Benzerroug M, Milazzo S. Treatment of macular hematoma complicating AMD by vitrectomy, subretinal r-TPA injection, intravitreal injection of bevacizumab combined with gas tamponade: Report of 4 cases. J Fr Ophtalmol. 2017; 40(2): 133-7.
4. Miniewicz J, Kubicka-Trząska A, Karska-Basta I et al. Leczenie krwotoków podsiatkówkowych w okolicy plamki doszklistkowymi iniekcjami rekombinowanego aktywatora plazminogenu, sześciofluorku siarki oraz ranibizumabu – doniesienie wstępne. Klin Oczna. 2015; 117(3): 165-8.
5. Meyer CH, Scholl HP, Eter N et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol. 2008; 86: 490-4.
6. Fujikawa M, Sawada O, Miyake T et al. Comparison of pneumatic displacement for submacular hemorrhages with gas alone and gas plus tissue plasminogen activator. Retina. 2013; 33(9): 1908-14.
7. de Silva SR, Bindra MS. Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent. Eye (Lond). 2016; 30(7): 952-7.
8. Czajka M, Pecold K. Zastosowanie enzymów w chirurgii witreoretinalnej. Klin Oczna. 2002; 104(1): 59-62.